← 프로그램 목록
ADCPhase 3Recruiting

Pirtobrutinib

SWOG Cancer Research Network

비교

Pirtobrutinib(SWOG Cancer Research Network)은 Chronic Lymphocytic Leukemia 표적 ADC로, Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: inhibits B-cell receptor signaling. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 66.4% (ClinicalTrials.gov NCT04666038). PK: t½ 20 h. 차별점: novel agents.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 9일 (5일 전)PK/독성 2026년 7월 9일 (5일 전)

Chronic Lymphocytic Leukemia

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma

Recruiting

Technology

구조모아 · MMAE (auristatin)

bispecific antibodies, chimeric antigen receptor T-cell therapies, and

Vedotin, and Belinostat

affinity maturation of antibody-producing B cells by somatic hypermutation

novel agents

Mechanism of Action

inhibits B-cell receptor signaling

macrophages, and neutrophils implicates Btk in platelet activation

apoptosis induced by venetoclax and AZD5991

biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel

resistance to ncBTKi can occur owing to second site aberrations in BTK, generating novel mutations such as L528x and T316x

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 52건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 1, Phase 2 · Phase 3 · Phase 2 · Phase 4…
  • Status: Completed · Not yet recruiting · Active, not recruiting
  • 주요 endpoint: Maximum Tolerated Dose (MTD) · Recommended dose for further study · To assess the preliminary anti-tumor activity of pirtobrutinib based on ORR as assessed by an Independent Review Committee (IRC). · To evaluate the safety of pirtobrutinib in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0 · To evaluate the safety of pirtobrutinib in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0
  • 등록된 결과: ORR 66.4%
  • PFS: 13.96
  • 핵심: This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previo…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Pirtobrutinib은 어떤 치료제인가요?
Pirtobrutinib(SWOG Cancer Research Network)은 Chronic Lymphocytic Leukemia 표적 ADC로, Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Pirtobrutinib의 임상 단계는?
Pirtobrutinib의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.